Mohamad Al-Rifai, MD
Neurology with Special Qualifications in Child Neurology · Sherman, TXNPI 1023016458
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $815, 9.8 times the $83 reported in 2019.
Across 117 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$273
- Jazz Pharmaceuticals Inc.$240
- Neurelis, Inc.$228
- AbbVie$202
- NS Pharma, Inc.$156
- Acadia Pharmaceuticals Inc$142
- plus $1K from 24 others
Across 2 payments — averaging $2500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$5K
What the payments were for
- Food & beverage$2,32397%
- Education$773%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 22 | $273 |
| Jazz Pharmaceuticals Inc. | 8 | $240 |
| Neurelis, Inc. | 10 | $228 |
| AbbVie | 6 | $202 |
| NS Pharma, Inc. | 6 | $156 |
| Acadia Pharmaceuticals Inc | 8 | $142 |
| UCB, Inc. | 5 | $131 |
| Johnson & Johnson | 3 | $112 |
| Sunovion Pharmaceuticals Inc. | 7 | $91 |
| Supernus Pharmaceuticals, Inc. | 5 | $86 |
| AstraZeneca | 3 | $75 |
| Abbott | 3 | $72 |
| Collegium Pharmaceutical, Inc. | 4 | $67 |
| Ipsen Biopharmaceuticals, Inc | 3 | $63 |
| Biogen | 3 | $62 |
| Tris Pharma Inc | 3 | $60 |
| Noven Therapeutics, LLC | 3 | $56 |
| Grifols USA, LLC | 2 | $44 |
| Pfizer | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Tanabe Pharma America, Inc. | 1 | $21 |
| Greenwich Biosciences, Inc. | 1 | $19 |
| Catalyst Pharmaceuticals, Inc. | 1 | $19 |
| Viiv Healthcare Company | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Sarepta Therapeutics, Inc. | 1 | $18 |
| SK Life Science, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$124
How this compares
$2,400 in reported general payments places this provider in the 65th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FycompaPerampanel | 34 | $43,984 |
| Lacosamide | 42 | $6,617 |
| Paliperidone ErPaliperidone | 27 | $6,087 |
| Oxcarbazepine | 47 | $5,803 |
| Levocarnitine | 42 | $2,441 |
| Divalproex Sodium ErDivalproex Sodium | 27 | $2,367 |
| Atomoxetine Hcl | 15 | $1,889 |
| Levetiracetam | 17 | $1,152 |
| Divalproex Sodium | 17 | $1,001 |
| Carbamazepine ErCarbamazepine | 14 | $776 |
| Lamotrigine | 39 | $711 |
| Baclofen | 27 | $683 |
| Glycopyrrolate | 21 | $641 |
| Aripiprazole | 17 | $628 |
| Quetiapine Fumarate | 15 | $599 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Sherman
- Roy EltermanDallas$5.9M
- Huda ZoghbiHouston$5.5M
- Diana CastroDenton$343K
- Shade MoodyHouston$194K
- Mary Kay KoenigHouston$171K
- Michael PerryFort Worth$162K
- Raphael SchiffmannDallas$88K
- Mauricio Delgado-AyalaDallas$75K
- Kaitlin BatleyDallas$74K
- Warren MarksFort Worth$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.